Dr. Kay Olmstead was an invited guest speaker at the annual International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) conference held in Trenton, NU in September 18-19, 2025. She presented Nano-CNS™ platform for on-demand CNS therapeutics and the results of the first-in-human single ascending dose pharmacokinetics data of NT-301. IPAC-RS conference brings together industry leaders, regulatory experts, and scientific pioneers to explore the complexities of nasal drug development.
ATLANTA and SAN DIEGO, Sept. 18, 2025 /PRNewswire/ — Mikart, LLC, a leading contract development and manufacturing organization (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical company, today announced positive safety and pharmacokinetics data from the ongoing Phase 1 clinical trial of NT-301, a proprietary powder nasal spray being developed for the treatment of Parkinson’s disease OFF episodes.
